This also included the oncogene Janus kinase 2 (JAK2), which is co-amplified with CD274 (PD-L1) in classical Hodgkin lymphoma, triple negative breast cancer, and renal cell cancer as well as in NSCLC [9, 13, 14, 24]. Here, JAK2 is linked to triple-negative breast carcinoma.